BioCentury
ARTICLE | Clinical News

Galafold migalastat regulatory update

June 15, 2015 7:00 AM UTC

Amicus submitted an MAA to EMA for Galafold migalastat as monotherapy to treat Fabry’s disease in patients who have amenable genetic mutations. The application has accelerated assessment in the EU, wh...